
Kent International Holdings, Inc. was founded in 1982 and is based in Far Hills, New Jersey. Kent International Holdings, Inc. (Kent International), formerly Cortech, Inc. was a biopharmaceutical company whose primary focus had been the discovery and development of therapeutics for the treatment of inflammatory disorders. It had directed its research and development efforts principally toward protease inhibitors and bradykinin antagonists. The Company has not identified the particular business, which it will seek to engage, nor has it conducted any market studies with respect to any business or industry to evaluate the possible merits or risks of the target business or industry, which the Company ultimately may operate.

Nycomed International Management GmbH the Swiss pharmaceutical company develops presciption and OTC medicines mainly focusing on cardiology, gastroenterology, osteoporosis, respiratory, and pain management therapies. It operates nearly 20 facilities in a dozen European countries, where it conducts its own research and drug testing. It also develops products in conjunction with partner pharmaceutical companies. The majority of Nycomed's revenues come from direct drug sales to doctors, hospitals, and pharmacies in Europe, the Americas, Russia, and Asia/Pacific as well as from licensing product rights to and from other companies.

Elan Pharmaceuticals is part of the the brains behind the brawn of drugmaker Elan Corporation. The US-based subsidiary provides research and discovery services, such as the identification and development of new drug candidates, to its Irish parent, which specializes in treatments for neurological and autoimmune diseases, as well as severe pain and infectious disease medications. The company investigates possible treatments for diseases such as Alzheimer's disease, Parkinson's disease, and multiple myeloma. The subsidiary also handles marketing of Elan's approved products in the US, including multiple sclerosis/Crohn's disease treatment Tysabri and chronic pain medication Prialt.

Genzyme Pharmaceuticals, a division of leading biotech firm Genzyme, couldn't agree more. The division, at its main production facility in Liestal, Switzerland, makes chemical intermediates and active pharmaceutical ingredients used in the production of a number of drugs, many manufactured by its parent. Its main products include natural and synthetic lipids and amino acid derivatives. It has also partnered with major pharmaceutical companies to develop custom manufacturing of drugs currently in development. Additionally, Genzyme Pharmaceuticals manufactures lipid-based drug delivery systems.

Gilead Palo Alto (formerly CV Therapeutics) is honed in on cardiovascular research. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). Gilead Palo Alto won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing potential therapies for ailments including heart failure and atrial fibrillation (irregular heartbeat). Gilead Palo Alto changed its name from CV Therapeutics after being acquired by Gilead Sciences in 2009.

Quick-Med Technologies, Inc. was founded in 1997 and is headquartered in Gainesville, Florida. Quick-Med Technologies, Inc., a life sciences company, develops technologies for the medical and consumer healthcare markets in the United States. Quick-Med Technologies's technologies under development include NIMBUS, a family of organic molecules or polymers that are bio-engineered to have antimicrobial, hemostatic, and other properties, which could be used in a range of medical device applications, including contact lenses, wound dressings, incontinence products, or disposable gloves; and Stay Fresh, a chemical formulation for textiles that provides a durable antimicrobial agent, which can be bonded to fibers or fabrics so as to retain the biocidal property through various launderings and is suitable for a range of applications, including apparel, sportswear, active wear, and work wear, as well as furnishings, such as linens, drapes, and towels. Its other technologies under development comprise NimbuDerm, a novel copolymer used as a persistent hand sanitizer; and MultiStat, a family of matrix metalloproteinase inhibitors that are used for the maintenance, healing, and repair of skin and eyes.

Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb Company, a global biopharmaceutical company, engages in discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company focuses on the areas of serious unmet medical need, such as cardiovascular disease, mental illness, cancer, HIV/AIDS, hepatitis B and C, rheumatoid arthritis, type 2 diabetes, solid organ transplantation, and Alzheimer's disease. Its lead products include cardiovascular medicines, including PLAVIX and AVAPRO/AVALIDE; ABILIFY, a medicine for the treatment of mental illness; ERBITUX, SPRYCEL, and IXEMPRA, which are cancer medicines; HIV medicines, such as REYATAZ, SUSTIVA, and ATRIPLA; BARACLUDE, a medicine for hepatitis B; ONGLYZA, a type 2 diabetes treatment; and ORENCIA, a medicine for rheumatoid arthritis. The company also has a pipeline with compounds in phase III clinical trials, including apixaban, dapagliflozin, ipilimumab, belatacept, and brivanib. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. Bristol-Myers Squibb Company has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Gilead Sciences, Inc.; AstraZeneca PLC; Pfizer, Inc.; and various biotech companies.

Hollis-Eden Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in San Diego, California. Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due to disease or the process of aging. The company focuses on developing a series of adrenal steroid hormones and hormone analogs that are derived from its Hormonal Signaling Technology Platform. It develops two clinical drug development candidates, TRIOLEX (HE3286), which is in initial clinical trials for the treatment of type 2 diabetes, ulcerative colitis, and rheumatoid arthritis; and APOPTONE (HE3235) that is in a clinical trial for late-stage prostate cancer. The company is also exploring APOPTONE for other cancers, such as breast cancer. In addition, Hollis-Eden Pharmaceuticals has a research program that is generating clinical leads for evaluation in preclinical models of various diseases, including metabolic and autoimmune conditions, as well as inflammatory diseases of the lung, bone metabolism, and regenerative medicine.

LifeSpan BioSciences likes the way genes express themselves. The firm helps drugmakers develop new product candidates faster by finding proteins and RNA in human tissue samples to identify gene expression associated with disease. It licenses access to its databases of gene expressions and protein localizations to drug developers. Also available are target validation and tissue pathology services. LifeSpan's clients include pharmaceutical companies in Asia, Europe, and North America.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)





